(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 December 2023 (14.12.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/240143 A1

(51) International Patent Classification:
C12N 5/0783 (2010.01) *A61K 39/00* (2006.01)
A61K 35/17 (2015.01) *C07K 14/725* (2006.01)

(21) International Application Number:
PCT/US2023/068074

(22) International Filing Date:
07 June 2023 (07.06.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/350,645 09 June 2022 (09.06.2022) US

(71) Applicant: **KITE PHARMA, INC.** [US/US]; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: **BANERJEE, Saikat**; Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **MURAKAMI, Jodi L.**; Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). **NOWYHED, Heba N.**; 2500 Beverwil Drive, Los Angeles, California 90034 (US). **OU, Da Ming**; Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(74) Agent: **SANNY, Tony** et al.; Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

WO 2023/240143 A1

(54) Title: METHODS OF PREPARING LYMPHOCYTES FOR CELL THERAPY CROSS REFERENCE TO RELATED APPLICATIONS

(57) Abstract: The present disclosure is directed to methods of preparing genetically engineered lymphocytes. In addition, methods of using the genetically engineered lymphocytes in T cell therapy for cancers are also disclosed.